You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Merck
Moodys
Mallinckrodt
Johnson and Johnson

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,089,268

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,089,268
Title: Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
Abstract:A sterile lipid emulsion composition made from fish oil enriched egg phosphatides; a natural oil, an osmotic agent such as glycerin and purified water, optionally adjusted to a pH of between 8.5 and 10.5 with sodium hydroxide. This composition can be administered parenterally to a host mammal.
Inventor(s): Katz; David P. (Flushing, NY)
Assignee:
Application Number:07/642,143
Patent Claims:1. In a sterile lipid emulsion for parenteral use, comprising:

(a) from 1 to 30% by weight of a neutral lipid mixture of fatty acid triglycerides containing omega-3 fatty acids, omega-6 fatty acids, medium chain length triglycerides or mixtures thereof;

(b) from 1 to 4% by weight of an egg yolk phosphatide emulsifier;

(c) up to 2.25% by weight of an osmolality modifier; and

(d) sterile water;

the improvement, wherein the egg yolk phosphatide is derived from the eggs of chickens whose diets have been supplemented with fish oils which are rich in eicosapentaenoic acid, docosahexaenoic acid or mixtures thereof, said egg yolk phosphatide containing from 10 to 100% higher amounts of omega-3 fatty acids than egg yolk phosphatides derived from the eggs of chickens whose diets have not been so supplemented.

2. The sterile lipid emulsion of claim 1, wherein the neutral lipid mixture is derived from at least one natural oil selected from the group consisting of fish oil, butter oil, coconut oil, cottonseed oil, lard, olive oil, sesame seed oil, soya bean oil, safflower oil and sunflower oil.

3. The sterile lipid emulsion of claim 2, wherein the natural oil is soybean oil.

4. The sterile lipid emulsion of claim 1, wherein the egg yolk phosphatide emulsifier is derived from the eggs of chickens whose diets have been supplemented with at least one fish oil selected from the group consisting of herring, cod, halibut, tuna, sardine, salmon, anchovy or menhaden oils.

5. The sterile lipid emulsion of claim 1, whose pH has been adjusted with base to a pH of from 8.5 to 10.5.

6. The sterile lipid emulsion of claim 1, wherein said osmolality modifier is glycerin.

7. In a sterile lipid emulsion for parenteral use, comprising:

(a) from 1 to 30% by weight of soybean oil;

(b) from 1 to 4% by weight of finely divided particles of an egg yolk phosphatide emulsifier;

(c) up to 2.25% by weight of glycerin as an osmolality modifier;

(d) sterile water; and

(e) a basic pH modifier in an amount sufficient to adjust the pH of the emulsion to a pH of from 8.5 to 10.5;

the improvement, wherein the egg yolk phosphatide is derived from the eggs of chickens whose diets have been supplemented with at least one fish oil selected from the group consisting of herring, code, one or more of the fish oils derived from herring, cod, halibut, tuna, sardine, salmon, anchovy or menhaden oil, said egg yolk phosphatide containing from 10 to 100% higher amounts of omega-3 fatty acids than egg yolk phosphatides derived from the eggs of chickens whose diets have not been so supplemented.

8. The sterile lipid emulsion of claim 7, wherein the egg yolk phosphatide emulsifier particles are within the range of from 0.2 to 1.0 micron in size.

9. The sterile lipid emulsion of claim 7, containing:

(a) 2% by weight soybean oil;

(b) 2% by weight of the egg yolk phosphatide emulsifier; and

(c) sodium hydroxide in an amount sufficient to adjust the pH of the emulsion to from 8.5 to 9.5.

Details for Patent 5,089,268

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial 2010-05-02 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial 2010-05-02 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Merck
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.